Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06493760
PHASE2

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

Official title: A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

130

Start Date

2024-09-03

Completion Date

2027-06

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

DRUG

SSGJ-707

bispecific antibody

DRUG

Bevacizumab

VEGF antibody

DRUG

Oxaliplatin

chemotherapy

DRUG

Capecitabine

chemotherapy

DRUG

Calcium Folinate

chemotherapy

DRUG

5-fluorouracil

chemotherapy

Locations (1)

Liu Tianshu

Shanghai, Shanghai Municipality, China